Penumbra, Inc.

NYSE:PEN Stock Report

Market Cap: US$8.1b

Penumbra Valuation

Is PEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PEN ($211.29) is trading above our estimate of fair value ($64.43)

Significantly Below Fair Value: PEN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PEN?

Other financial metrics that can be useful for relative valuation.

PEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.1x
Enterprise Value/EBITDA76.1x
PEG Ratio13.2x

Price to Sales Ratio vs Peers

How does PEN's PS Ratio compare to its peers?

The above table shows the PS ratio for PEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.6x
MASI Masimo
3.8x5.9%US$7.5b
GKOS Glaukos
22.3x18.3%US$7.6b
GMED Globus Medical
4.5x8.1%US$10.1b
TFX Teleflex
3.7x5.5%US$11.1b
PEN Penumbra
7.2x12.2%US$8.1b

Price-To-Sales vs Peers: PEN is good value based on its Price-To-Sales Ratio (7.2x) compared to the peer average (8.6x).

Price to Earnings Ratio vs Industry

How does PEN's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: PEN is expensive based on its Price-To-Sales Ratio (7.2x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is PEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.2x
Fair PS Ratio4.4x

Price-To-Sales vs Fair Ratio: PEN is expensive based on its Price-To-Sales Ratio (7.2x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PEN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$211.29
US$213.40
+1.0%
13.5%US$244.00US$150.00n/a15
Oct ’25US$191.56
US$199.40
+4.1%
13.0%US$240.00US$150.00n/a15
Sep ’25US$202.32
US$192.00
-5.1%
11.2%US$224.00US$150.00n/a13
Aug ’25US$171.25
US$187.46
+9.5%
10.4%US$215.00US$150.00n/a13
Jul ’25US$177.09
US$268.77
+51.8%
8.1%US$300.00US$225.00n/a13
Jun ’25US$189.47
US$270.83
+42.9%
7.9%US$300.00US$225.00n/a12
May ’25US$205.29
US$280.08
+36.4%
7.5%US$320.00US$240.00n/a14
Apr ’25US$217.39
US$280.01
+28.8%
7.5%US$320.00US$240.00n/a14
Mar ’25US$236.67
US$280.31
+18.4%
7.8%US$320.00US$240.00n/a13
Feb ’25US$254.36
US$284.00
+11.7%
8.5%US$320.00US$240.00n/a13
Jan ’25US$251.54
US$275.85
+9.7%
9.2%US$320.00US$240.00n/a13
Dec ’24US$227.75
US$258.62
+13.6%
11.8%US$320.00US$207.00n/a13
Nov ’24US$194.06
US$301.17
+55.2%
13.1%US$367.00US$240.00n/a12
Oct ’24US$241.91
US$334.83
+38.4%
9.7%US$390.00US$265.00US$191.5612
Sep ’24US$264.12
US$341.18
+29.2%
7.6%US$390.00US$308.00US$202.3211
Aug ’24US$298.33
US$348.45
+16.8%
7.2%US$390.00US$310.00US$171.2511
Jul ’24US$344.06
US$326.10
-5.2%
5.8%US$367.00US$303.00US$177.0910
Jun ’24US$314.24
US$320.30
+1.9%
4.2%US$350.00US$303.00US$189.4710
May ’24US$285.46
US$297.90
+4.4%
4.6%US$325.00US$285.00US$205.2910
Apr ’24US$278.69
US$293.50
+5.3%
3.9%US$320.00US$279.00US$217.3910
Mar ’24US$258.38
US$290.82
+12.6%
2.6%US$303.00US$279.00US$236.6711
Feb ’24US$257.30
US$256.82
-0.2%
9.6%US$285.00US$195.00US$254.3611
Jan ’24US$222.46
US$236.70
+6.4%
10.0%US$270.00US$195.00US$251.5410
Dec ’23US$210.11
US$206.80
-1.6%
9.5%US$235.00US$167.00US$227.7510
Nov ’23US$161.85
US$223.00
+37.8%
8.7%US$260.00US$195.00US$194.0610
Oct ’23US$189.60
US$207.22
+9.3%
16.5%US$260.00US$163.00US$241.919

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y